Introduction
The N-myc gene, a member of the MYC gene family of transcription factors, encodes a nuclear phosphoprotein frequently ampli®ed in neuroblastomas and in several human tumors of neuroendocrine (Lee et al., 1984; Nau et al., 1986) and mesenchymal origin (Dias et al., 1990; Hayashi et al., 1990) . Clinical studies have shown the correlation between N-myc ampli®cation, rapid tumor progression and poor outcome in human neuroblastomas Brodeur et al., 1984; Seeger et al., 1985) , identifying N-myc as a potential nuclear trans-acting regulatory factor (Bernards et al., 1986; Akeson and Bernards, 1990; Sato et al., 1992) .
N-myc, as are many other proto-oncogene products, is a very short-lived protein with a half-life between 30 and 50 min, as determined in several N-myc ampli®ed neuroblastoma cell lines (Ikegaki et al., 1986; Slamon et al., 1986; Ramsay et al., 1986) . Unlike the short halflife described in N-myc ampli®ed cell lines, the N-myc half-life in some cell lines is signi®cantly prolonged, resulting in an elevated steady-state protein level, perhaps due to an altered degradation signal (Cohn et al., 1990) .
The multicatalytic protease complex (MPC), or proteasome, is the major nonlysosomal protease which degrades (Rivett, 1990 (Rivett, , 1993 Hochstrasser, 1995) or processes (Fan and Maniatis, 1991; Michalek, 1993; Palombella et al., 1994) short-lived proteins by ATP/ ubiquitin-dependent proteolysis. Covalent conjugation to the polypeptide ubiquitin seems to be an obligatory step in the degradation of most nuclear and cytosolic short-lived proteins (Ciechanover et al., 1991; Hershko and Ciechanover, 1992; Jentsch, 1992) , although in a few cases tagging by ubiquitin is not an absolute requirement for degradation by the proteasome in vitro Rosenberg-Hasson et al., 1989; Jariel-Encontre et al., 1995) . The involvement of an ATP-dependent degradation pathway in vitro in the turnover of N-myc and other nuclear regulatory proteins (c-Myc, c-Fos, E1A and p53) has been demonstrated, however high molecular weight ubiquitin conjugates of N-myc were not observed (Ciechanover et al., 1991) . In addition, a recent in vitro study has also implicated calpain in N-myc degradation (Gonen et al., 1997) .
The involvement of speci®c proteinases in cellular processes is inferred frequently by the use of inhibitors. Peptide aldehyde derivatives, because of their low toxicity, are frequently used in animal and cell culture models to identify and characterize speci®c proteinase activities participating in a particular cellular or physiologic event. However, the conclusions drawn from such studies have been compromised by the speci®cities of the inhibitors employed. Indeed, although some of the biochemical properties of the proteasome are well characterized (Orlowski, 1990; Orlowski et al., 1993) , the physiologic functions of this proteinase complex have been dicult to study due to the lack of speci®c inhibitors. Recently, a novel streptomyces metabolite, lactacystin, discovered on the basis of its ability to induce neurite outgrowth in the murine neuroblastoma cell line Neuro-2A (Katagiri et al., 1995; Fenteany et al., 1994; Fenteany and Schreiber, 1996) , has emerged as a highly speci®c, irreversible inhibitor of 26S proteasome chymotrypsin-like and trypsin-like activity, without aecting lysosomal and nonlysosomal cysteine proteases, cathepsin or calpain (Fenteany et al., 1995) . The inhibitory eect of lactacystin on ubiquitin/ATP-dependent degradation of several proteins has been demonstrated both in mammalian cells (Blagosklonny et al., 1996; Bies and Wol, 1997; Oda et al., 1996; Mimnaugh et al., 1996; Lee and Goldberg, 1996; Jeers et al., 1997; Whitesell et al., 1997) and in yeast .
In this investigation, we studied the mechanism involved in the in vivo degradation of the short-lived transcription factor N-myc, using inhibitors of lysosomal, calpain and proteasome pathways. Our results have identi®ed the 26S proteasome as a major pathway in vivo responsible for rapid degradation of N-myc.
Results

Inhibition of proteasome activity blocks degradation of N-myc and promotes accumulation of polyubiquitinated N-Myc
To investigate the role of the proteasome in the in vivo degradation of N-myc protein, we treated IMR32 cells with 100 mM ALLnL for 4 h. As shown in Figure 1a , N-myc steady-state level, measured by Western blot in total lysate, was increased by ALLnL treatment by 3 ± 4-fold (compare lanes 4 and 5 and graphical representation). Similar experiments were performed on three separate occasions and resulted in a mean increase in N-myc steady-state level of 4.5-, 4.6-and 4.7-fold. ALLnL not only inhibits the proteasome (Orlowski et al., 1993; Rock et al., 1994) , but is also an inhibitor of calpain (Wang et al., 1994) and cathepsin (Sasaki et al., 1990) . To con®rm that the results we obtained were due speci®cally to proteasome inhibition, we also examined the eect of lactacystin (LC, 10 mM), a speci®c inhibitor of the proteasome (Fenteany et al., 1995) , on the steady-state level of N-myc. We observed that 4 h exposure to LC also increased the steady-state level of N-myc protein in vivo (Figure 1a , compare lanes 4 and 6). Immunoprecipitation of N-myc, followed by Western blotting, gave similar results. Four hour treatment with either ALLnL (lane 2) or LC (lane 3) resulted in an elevation in N-myc protein when compared to control (lane 1).
Longer exposure of the ®lm revealed that in the Nmyc immunoprecipitates, two higher molecular weight N-myc-speci®c bands could be seen following both ALLnL and LC treatment, but not in the untreated sample (Figure 1b, arrowheads) . In order to determine whether these bands represent ubiquitinated N-myc species, we probed N-myc immunoprecipitates with a polyclonal antibody to ubiquitin (Figure 1c) . To our surprise, we did not observe a series of discrete bands of increasing molecular weight, but instead a diuse signal extended toward the top of the gel in the lanes treated with either ALLnL or LC (compares lanes 1 ± 3). In a further attempt to explore this issue, we treated IMR32 cells with ALLnL (100 mM) for variable amounts of time (30 min ± 4 h) and then probed Nmyc immunoprecipitates for either N-myc or ubiquitin ( Figure 2 ). The data demonstrate progressive accumulation of N-myc protein, as well as a progressive increase in polyubiquitinated N-myc. Nevertheless, appearance of discrete higher molecular weight bands corresponding to polyubiquitinated N-myc was still dicult to observe. This has been seen previously with other ubiquitinated proteins (Ciechanover et al., 1984; Mimnaugh et al., 1996) and probably occurs when a variable number of ubiquitin molecules are added to Exponentially growing IMR32 cells were cultured for 4 h without (lanes 1,4) and with 100 mM ALLnL (lanes 2,5) or 10 mM LC (lanes 3,6). 1250 mg of total proteins were immunoprecipitated with N-myc Ab (lanes 1 ± 3); 100 mg of total proteins from cell lysates were also used for Western blotting (lanes 4 ± 6). Proteins were resolved by reducing 8% SDS ± PAGE, electrotransferred to nitrocellulose membranes and probed for N-myc. (b) Samples 1 ± 3 described in (a) were subjected to a longer exposure to show higher molecular weight N-myc-speci®c bands (Arrowheads). (c) Anti-ubiquitin immunoblots of N-myc immunoprecipitates (from 1 mg of lysate) were performed from untreated (lane 1) and 4 h ALLnL-(lane 2) or LC-treated (lane 3) samples described in the legend to a. Following 8% SDS ± PAGE and electrotransfer, membranes were probed with anti-ubiquitin antibody (lanes 1 ± 3). The position of the molecular weight markers is shown on the right the substrate protein during the process of polyubiquitination (Ciechanover et al., 1994) . On the other hand, the ubiquitin signal observed in Figure 1c , lanes 2 and 3 could be due to non-speci®c association of random polyubiquitinated proteins (accumulated following proteasome inhibition) with the N-myc immunoprecipitates. In order to rule out the latter possibility, we immunoprecipitated N-myc from 1 mg of protein extract prepared from untreated IMR32 cells, and mixed the immunoprecipitate with 1 mg of SKNSH cell lysate prepared from cells treated with ALLnL (100 mM) for 4 h. SKNSH is a neuroblastoma cell line in which N-myc is not ampli®ed (Wada et al., 1993) , and in which we could not ®nd detectable N-myc signal either in total lysate or following immunoprecipitation, even after ALLnL treatment (data not shown). However, ALLnL treatment of these cells did result in`general' polyubiquitination of total cell proteins equivalent to that observed in IMR32 cells (see Figure 3b , lanes 2 and 4). After mixing, the N-myc immunoprecipitates were washed as described in Materials and methods and analysed for both N-myc and ubiquitin content. Figure 3a , lanes 1 ± 6 depict Nmyc protein in either N-myc immunoprecipitates (lanes 1 ± 3) or total lysate (lanes 4 ± 6). Lanes 1 and 4 were prepared from untreated IMR32 cells, lanes 2 and 5 were prepared from IMR32 cells treated for 4 h with ALLnL, and lanes 3 and 6 were prepared from a 1 : 1 mixture of lysates arising from untreated IMR32 cells and ALLnL-treated SKNSH cells. The data demonstrate elevated N-myc protein only in samples prepared from ALLnL-treated IMR32 cells (lanes 2 and 5). Lanes 7 ± 9 represent an anti-ubiquitin Western blot of the N-myc immunoprecipitates depicted in lanes 1 ± 3. Lane 7 was prepared from untreated IMR32 cells, lane 8 was prepared from ALLnL-treated IMR32 cells, and lane 9 was prepared from a 1 : 1 mixture of untreated IMR32 cells and ALLnL-treated SKNSH cells. The data clearly show that a strong ubiquitin-speci®c signal was observed only when N-myc was immunoprecipitated from ALLnL-treated IMR32 cells (lane 8), and not when a control N-myc immunoprecipitate was mixed with random polyubiquitinated proteins from an ALLnL-treated lysate lacking N-myc (lane 9). These results support the hypothesis that the strong ubiquitin signal seen in N-myc immunoprecipitates of IMR32 cells following proteasome inhibition is not adventitious.
Lysosomal and calpain proteases are not involved in N-myc degradation in vivo
To rule-out the possibility that N-myc steady-state level was regulated by lysosomal or nonlysosomal proteases in addition to the ubiquitin-dependent proteasome pathway, we treated IMR32 cells with either 100 mM chloroquine, a weak base which inhibits lysosomal acidic proteases (Poole and Ohkuma, 1981) (Figure 4a , lane 2), 175 mM leupeptin, a calpain and lysosomal protease inhibitor (Atsma et al., 1995; Umezawa, 1976; Seglen, 1983; Tsubuki et al., 1994 Following a 4 h exposure, none of these agents signi®cantly aected the steady-state level of N-myc protein when compared to the control sample ( Figure  4a , lane 1). However, because ALLnL has been shown to inhibit neutral cysteine proteases such as calpain (Wang, 1990; Figuereido-Pereira et al., 1994) , as well as acid cysteine proteases such as cathepsin (Sasaki et al., 1990; Wang et al., 1994) , we examined additional membrane-permeant inhibitors. Cells were exposed for 4 h to either calpeptin (10 mg/ml), a slightly more potent calpain inhibitor than ALLnL, E64D (35 mM), a lipid-soluble cathepsin and calpain inhibitor or to CBZ (40 mM), a mixed cathepsin, calpain and proteasome inhibitor, similar in speci®city to ALLnL. The data in Figure 4b demonstrate that exposure to calpeptin (lane 2) failed to induce accumulation of N-myc when compared to the control sample (lane 1), in contrast to exposure to E64D (lane 3) and CBZ (lane 4), which both resulted in a small elevation of the N-myc protein steady state level. Only CBZ, because of its ability to inhibit the proteasome, caused accumulation of ubiquitinated N-myc when N-myc immunoprecipitates were analysed (Figure 4b , compare lane 8 to lanes 5 ± 7). These ®ndings were con®rmed in a subsequent experiment with a dierent N-myc ampli®ed neuroblastoma cell line, SKNDZ (data not shown). The ability of E64D to slightly stimulate N-myc accumulation (Figure 4b, lane 3) raises the possibility of a secondary, currently unidenti®ed nonproteasomal degradative pathway involving neither calpain nor lysosomal proteases.
Proteasome inhibition increases N-myc half-life in IMR32 cells
If N-myc is degraded by the proteasome in vivo, then inhibition of the proteasome would be expected to stabilize N-myc. The half-life of N-myc protein in the presence or absence of proteasome inhibition was therefore determined (Figure 5 ). IMR32 cells, untreated or pre-treated for 4 h with 100 mM ALLnL, were incubated for an additional hour in media containing 100 mCi/ml of [ 35 S]methionine (+ ALLnL), and then chased in non-radioactive complete medium in the absence of ALLnL. N-myc was immunoprecipitated from labeled extracts at various times after initiating the chase period (see Materials and methods), and the amount of radioactive N-myc immunoprecipitated at each time point was quanti®ed and used to determine the half-life of the protein. In the absence of the inhibitor ( Figure 5, closed circles) , the half-life of N-myc was found to be 33 min, Lysates Ubiquitin a b Figure 3 Speci®city of N-myc ubiquitination. (a) IMR32 and SKNSH cells were treated with 100 mM ALLnL for 4 h. To rule-out artifactual precipitation of ubiquitinated proteins, 1 mg of untreated IMR32 cell extracts was mixed with 1 mg of ALLnL-treated SKNSH cell extracts (lanes 3,9). As described in Materials and methods, N-myc was immunoprecipitated from these two samples. All samples were resolved on 8% SDS ± PAGE, and membranes, after electrotransfer, were probed for N-myc (lanes 1 ± 6), or for ubiquitin (lanes 7 ± 9). One hundred mg of total lysates, probed directly with N-myc Ab, are shown in lanes 4 ± 6. In sample 6, 100 mg of untreated IMR32 lysate were mixed with 100 mg of ALLnL-treated SKNSH lysate. Controls are shown in lanes 1,4,7; IMR32 ALLnL-treated samples in lanes 2,5,8; IMR32 controls plus SKNSH ALLnL-treated in lanes 3,6,9. (b) To show the`general' polyubiquitination of total cell proteins, 100 mg of both IMR32 and SKNSH ALLnL-treated and untreated lysates were electrophoresed and probed with ubiquitin antibody. IMR32 and SKNSH controls are shown in lanes 1 and 3; IMR32 and SKNSH ALLnL-treated samples are in lanes 2 and 4 respectively consistent with values previously obtained by others (Ikegaki et al., 1986; Slamon et al., 1986; Ramsay et al., 1986) . In contrast, the half-life of N-myc was 68 min in the presence of ALLnL ( Figure 5 , open triangles). Thus, the N-myc protein half-life was increased by at least 2-fold in IMR32 cells in response to proteasome inhibition.
Proteasomal degradation of N-myc occurs in the nucleus in IMR32 cells
Although N-myc is a nuclear protein, its normal site of degradation is not known. Since proteasomes have been demonstrated to exist in both nucleus and cytosol (Palmer et al., 1996; Knuehl et al., 1996) , it was of interest to determine whether proteasome inhibition led to accumulation of N-myc in one or both cellular compartments. Fluorescence microscopic examination of SKNSH cells plated on coverslips, did not detect an accumulation of N-myc in ALLnL treated (4 h) cells (Figure 6c ). However, examination of IMR32 cells revealed that N-myc accumulation was detectable only in the nuclear compartment of ALLnL treated cells (Figure 6g) . Thus, N-myc degradation appears to be restricted entirely to the nucleus, and does not require transport of ubiquitin-tagged protein to the cytoplasm prior to degradation.
Discussion
The N-myc protein is a normally short-lived transcription factor which is frequently over-expressed in neuroblastoma . In vitro, N-myc has been shown to be degraded by the proteasome. Thus the ATP-dependent degradation of N-myc, which is thought to be mediated by the proteasome, can be inhibited by immunologic depletion of the E1 ubiquitin-activating enzyme (Ciechanover et al., 1991 (Ciechanover et al., , 1994 . At the same time, as previously shown for ornithine decarboxylase Rosenberg-Hasson et al., 1989) , c-Jun (Jariel-Encontre et al., 1995) and p53 (Gonen et al., 1997) , in vitro degradation of N-myc can also proceed via a calpaindependent ubiquitin-independent pathway (Gonen et al., 1997) .
Since these experiments utilized by in vitro translation of N-myc protein in rabbit reticulocyte lysate preparations, the predominant pathway responsible for N-myc degradation in neuroblastoma cells has remained to be characterized. The data presented in this study demonstrate that, in vivo, in N-myc-ampli®ed neuroblastoma cells, N-myc protein appears to be degraded primarily by the proteasome, with little participation of calpain or other proteases. Several calpain and cathepsin inhibitors, at concentration not inhibiting the proteasome, failed to block N-myc degradation in vivo, while several proteasome inhibitors, including the speci®c inhibitor lactacystin, led to an elevation in N-myc level. This elevation was accompanied by an increase in polyubiquitinated N-myc, as visualized by probing N-myc immunoprecipitates with a ubiquitin-speci®c antibody. The N-myc protein accumulated following proteasome inhibition remained localized in the cell nucleus, demonstrating that ubiquitination and degradation of N-myc normally occurs in this compartment and not in the cytosol. Consistent with these data is the fact that proteasomes have been identi®ed not only in cytosolic but also in nuclear fractions of many cells Palmer et al., 1996; Knuehl et al., 1996) . Although it may appear paradoxical that breakdown of a nuclear protein might, under certain conditions, be achieved by a cytoplasmic protease such as calpain, a minor fraction of this protease has been reported to be present in the nucleus of several cells (Kubbutat and Voudsen, 1997) . Further, the involvement of calpain as a secondary degradation pathway, in addition to the proteasome, has been demonstrated for nuclear matrix protein (Mellgren, 1991; Mellegren et al., 1993) , certain transcription factors (Carillo et al., 1994) and, more recently, for p53 (Pariat et al., 1997; Gonen et al., 1997) . Therefore, our data do not rule out the possible participation of calpain, under certain experimental and physiologic conditions, in N-myc degradation in vivo.
The results in this study demonstrate that inhibition of the 26S proteasome causes an increased steady-state level of N-myc protein. Cohn and colleagues have described a novel human N-myc unampli®ed neuroblastoma cell line, NBL-S, with a signi®cantly prolonged N-myc half-life, but with similar size of transcript and protein product compared to normal Nmyc in ampli®ed cell lines (Cohn et al., 1990) . However, the normal degradation of other short-lived proteins demonstrated that this is not a general defect in proteolysis. It will be interesting to determine whether the N-myc protein found in these cells is not able to be targeted to the ubiquitin-proteasome pathway, either because of mutation or because of defective enzymatic coupling of ubiquitin to N-myc.
Materials and methods
Reagents and drugs
Culture media were purchased from Bio¯uids, Inc. 
and E64D (L-LeucylAmido-3-Methyl-Butane-Ethyl-Ester) were purchased from Sigma Chemical Co. Calpeptin (Benzyloxicarbonyldipeptidyl aldehyde) was purchased from Calbiochem-Novabiochem Corporation. CBZ (N-CBZ-L-leucyl-L-leucyl-L-Tyrosinediazomethylketone) was from Molecular Probes. Lactacystin [LC] was purchased from Dr EJ Corey, Harvard University. Chloroquine, Leupeptin (N-acetyl-L-leucyl-Lleucyl-L-argininal) and PMSF (Phenylmethanesulfonyl uoride) were purchased from Sigma Chemical Co. Anti-N-myc monoclonal antibody (clone NCM II 100) was purchased from Calbiochem. Rabbit anti-ubiquitin polyclonal antibody was purchased from Sigma Chemical Co.
Other antibodies used in this study were: rabbit anti-mouse IgG 1 from Cappel, horseradish peroxidase-conjugated sheep anti-mouse antibody and horseradish peroxidaseconjugated donkey anti-rabbit antibody from Amersham Life Science. Protein A-Sepharose beads were purchased from Pharmacia. BCA Protein Assay reagent and Western blot chemiluminescence reagents were purchased from Pierce Chemical Co. Protran TM nitrocellulose membranes were obtained from Schleicher and Schuell. All the other chemicals used in this study were purchased from Sigma Chemical Co.
Cell culture
The N-myc ampli®ed neuroblastoma cell lines IMR32 and SKNDZ, and the N-myc unampli®ed neuroblastoma cell line SKNSH, were obtained from the American Type Culture Collection, Rockville, MD. The cells were maintained in RPMI 1640 medium containing 10% bovine calf serum, 2 mM L-glutamine and 10 mM HEPES pH 7.5, under standard tissue culture conditions. Cells in log phase were treated with speci®c protease inhibitors as follows: ALLnL (20 mM), ALLM (20 mM), calpeptin (10 mg/ml), E64D (10 mM), CBZ (20 mM) and PMSF (0.5 M), dissolved in Me 2 SO, were diluted in complete medium to 100 mM, 100 mM, 10 mg/ml, 35 mM, 40 mM and 2 mM respectively. LC (2 mM), chloroquine (20 mM) and leupeptin (10 mg/ml), dissolved in water, were diluted in complete medium to 10 mM, 100 mM and 175 mM respectively.
Immunoprecipitation and immunoblotting
Cells were treated for 4 h with dierent protease inhibitors and were then trypsinized, washed twice in ice-cold phosphate-buered saline (PBS), and lysed with ice-cold RIPA lysis buer (1% NP40; 0.5% Nadeoxycholate; 0.1% SDS; 1 mM EDTA, all in 26PBS) Figure 5 N-myc half-life increases in response to proteasome inhibition. After a 4 h pretreatment with and without ALLnL (100 mM), IMR32 cells were labeled for 1 h in the presence of 35 S methionine (100 mCi/ml) and then chased in nonradioactive normal media for 0, 30, 60 or 90 min. Cell extracts were prepared as described in Materials and methods, and labeled Nmyc was immunoprecipitated from 800 mg of total cell lysates. Immunoprecipitates were resolved on 10% SDS ± PAGE gels, and the gels were dried and visualized by autoradiography. Band densities of control (*) and ALLnL-treated (D) samples were quantitated by densitometric analysis and plotted. The amount of N-myc at the zero time point was considered 100%. The calculated half-life of N-myc protein in IMR32 was 33 min; after ALLnL treatment the N-myc half-life was extended to 68 min containing 1 mM PMSF, 20 mg/ml leupeptin and 20 mg/ml aprotinin. Cell lysates were passed ten times through a 22 gauge needle to shear chromosomal DNA and were clari®ed by centrifugation (at 48C) at 14 000 g for 30 min. Protein concentration of the supernatant was determined by BCA assay using bovine serum albumin as standard. N-myc was immunoprecipitated from cell lysates with 2 mg anti-N-myc antibody followed by rabbit antimouse IgG 1 previously bound to protein A-Sepharose beads. The immunoadsorbed pellets were washed ®ve times with RIPA buer and heated to 958C in 16 reducing Laemmli loading buer. Aliquots of cell lysates (100 mg) diluted in 56 reducing loading buer, and immunoprecipitates were fractionated by 8% SDS ± PAGE and electrotransferred to Protran TM nitrocellulose membranes. The membranes used for anti-ubiquitin Western blots were ®rst autoclaved in water for 20 min (Mimnaugh et al., 1996) . Western blotting was carried out as previously described (Mimnaugh et al., 1996) , and proteins were visualized by chemiluminescence using a Figure 6 Proteasomal degradation of N-myc occurs in the nucleus in IMR32 cells. SKNSH (a ± d) and IMR32 (e ± h) cells, grown on coverslips, were treated with ALLnL (100 mM for 4 h), and N-myc immuno¯uorescence was detected as described in Materials and methods. (a,b) untreated SKNSH; (c,d) ALLnL-treated SKNSH; (e,f) untreated IMR32; (g,h) ALLnL-treated IMR32. (a,c,e,g) N-myc; (b,d,f,h) cells stained with DAPI to localize nucleus commercial kit. X-OMAT TM AR ®lms (Kodak) were scanned into a computer and the images were quanti®ed using image analysis software (NIH Image).
N-myc protein half-life determination
The N-myc ampli®ed human neuroblastoma cell line IMR32 was treated for 4 h with 100 mM ALLnL and then transferred to methionine-free medium (containing ALLnL) for 30 min. The cells were subsequently incubated with [ 35 S]methionine (100 mCi/ml) for 1 h, washed and resuspended in complete media for 0, 30, 60 or 90 min. At the end of each time point cells were harvested and lysed, and 35 S-methionine-labeled N-myc was immunoprecipitated and electrophoresed as described above. The 10% SDS ± PAGE gel was ®xed with a solution of 10% acetic acid, 25% of methanol and 5% glycerol, and enhanced with Enlightening solution (Dupont, NEN), prior to drying and autoradiography. Band density for both control and ALLnL-treated samples was analysed by NIH Image and N-myc half-life was determined by regression analysis of log transformed Nmyc-speci®c band intensities.
Immuno¯uorescence microscopy
Cells that had been grown on sterile coverslips were ®xed with 3.7% formaldehyde in PBS for 10 min and permeabilized with 0.2% Triton X-100 for an additional 10 min at room temperature. Nonspeci®c binding sites were then blocked by incubating the cells with 1% bovine serum albumin in PBS for 1 h at 48C before processing for immuno¯uorescence labeling. Primary antibody was added to the coverslip and incubated for 1 h at 48C. After antibody incubation, the coverslip was washed twice for 2 min with PBS and incubated at 48C for 1 h with Cy3-conjugated goat anti-mouse immunoglobulin (Jackson Immuno-Research Laboratories Inc.). After washing out unbound secondary antibody, cells were labeled with 0.4 mg/ml 4', 6-diamidino-2-phenylindole hydrochloride (Pierce) for 10 min. The coverslips were then washed with PBS, rinsed quickly with water, air-dried and mounted onto slides using SlowFade (Molecular Probes).
